No Data
No Data
Earnings Preview: SLN to Report Financial Results Pre-market on February 27
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Goldman Sachs Initiates Coverage On Silence Therapeutics With Sell Rating, Announces Price Target of $6
Sell Rating on Silence Therapeutics Due to Suboptimal Dosing, Financial Constraints, and Competitive Lag